Lipoprotein(a), Hormone Replacement Therapy, and Risk of Future Cardiovascular Events
- 8 July 2008
- journal article
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 52 (2) , 124-131
- https://doi.org/10.1016/j.jacc.2008.04.009
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Low-Dose Aspirin in the Primary Prevention of CancerJAMA, 2005
- Lipoprotein (a) and coronary heart disease among women: beyond a cholesterol carrier?European Heart Journal, 2005
- Cardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy: Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II)--CorrectionPublished by American Medical Association (AMA) ,2002
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998
- Hypertriglyceridemia and elevated lipoprotein (a) are risk factors for major coronary events in middle-aged menThe American Journal of Cardiology, 1996
- Apolipoproteins and ischaemic heart disease: implications for screeningThe Lancet, 1994
- Predictive value of apolipoproteins in a prospective survey of coronary artery disease in menThe American Journal of Cardiology, 1992
- Lipoprotein(a). Clinical approach to a unique atherogenic lipoproteinJAMA, 1992
- cDNA sequence of human apolipoprotein(a) is homologous to plasminogenNature, 1987